Article, News
Prescient Therapeutics (ASX:PTX) announces US-based Dr Ellen Feigal as new inclusion to Board
ASX-listed clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has informed about the appointment of Dr Ellen Feigal to PTX’s Board. Notably, Dr Feigal is an…
Article, News
Prescient Therapeutics bolsters board with appointment of experienced US-based pharma executive
Prescient Therapeutics Ltd (ASX:PTX) has strengthened its board through the appointment of experienced pharma executive Dr Ellen Feigal as a US-based independent, non-executive director, effective today….
Article, News
Prescient Therapeutics (ASX:PTX) makes progress in March 2023 quarter
Prescient Therapeutics (ASX: PTX), the Australian listed entity into clinical stage oncology, has released its Activities Report for the quarter ended March 2023. Aside from…
Article, News
Three life sciences stocks that may be undervalued
Life science stocks have suffered heavily in 2022 due to investors shifting out of risk assets, resulting in a bear market for biotech and medical…
Article, News
ASX Quarterly Wrap: Growing pipeline, milestones, and bullish guidance were the themes for these stocks
It’s the quarterly season again as the ASX market announcements page becomes increasingly flooded with update lodgements. To save you the trouble of trudging through…
Article, News
Aussie biotech presents CAR-T platforms at prestigious global conference
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has just presented at the Cell & Gene Meeting on the Mediterranean, after being invited to present…
Article, News
Health Kick Podcast: Prescient Therapeutics’ PTX-100 continues to show encouraging results following FDA Orphan Drug Designation
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast….
Article, News
Cancer cure no longer science fiction: Prescient boss
Cell and gene therapy is changing the game when it comes to cancer treatment and it’s closing in on possibly finding a cure, says ASX-listed…
Article, News
Prescient Therapeutics hopes to accelerate bid for US FDA study approval for targeted therapy PTX-100
Prescient Therapeutics is hoping to follow in the footsteps of Neuren Pharmaceuticals after positive results from its latest Phase 1b clinical trial. Prescient Therapeutics (ASX:PTX) will…